Onesource Specialty Pharma: DRL Semaglutide Delay Has No Material Impact

Onesource Specialty Pharma Limited has clarified that the delay in commercial supplies of Semaglutide announced by Dr. Reddy's Laboratories (DRL) will not have any material financial or operational impact on its business. The company highlighted its commitment to its partnership with DRL and stated it has sufficient demand from other customers, including for Canada. Onesource is also expanding its manufacturing capacities starting this quarter to meet future demand, including DRL's requirements once they are ready. The company remains focused on its growth plans and serving global customers.